These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 26927896)
1. Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. von Wolff M; Capp E; Jauckus J; Strowitzki T; Germeyer A; Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():146-9. PubMed ID: 26927896 [TBL] [Abstract][Full Text] [Related]
2. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy. Danis RB; Pereira N; Elias RT Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354 [TBL] [Abstract][Full Text] [Related]
3. Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation - cohort study. Muteshi C; Child T; Ohuma E; Fatum M Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():10-14. PubMed ID: 30227359 [TBL] [Abstract][Full Text] [Related]
5. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834 [TBL] [Abstract][Full Text] [Related]
6. Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation. Almog B; Azem F; Gordon D; Pauzner D; Amit A; Barkan G; Levin I Fertil Steril; 2012 Oct; 98(4):957-60. PubMed ID: 22763097 [TBL] [Abstract][Full Text] [Related]
7. Ovarian stimulation for fertility preservation in women with cancer: A systematic review and meta-analysis comparing random and conventional starts. Alexander VM; Martin CE; Schelble AP; Laufer AB; Hardi A; McKenzie LJ; Hipp HS; Kawwass JF; Spencer JB; Jungheim ES J Gynecol Obstet Hum Reprod; 2021 Oct; 50(8):102080. PubMed ID: 33545413 [TBL] [Abstract][Full Text] [Related]
8. Different stimulation protocols for oocyte cryropreservation in oncological patients: a retrospective analysis of single university centre. Simi G; Obino ME; Casarosa E; Litta P; Artini PG; Cela V Gynecol Endocrinol; 2015; 31(12):966-70. PubMed ID: 26370262 [TBL] [Abstract][Full Text] [Related]
10. [Fertility preserving methods in women with breast cancer before gonadotoxic therapy]. Halászová N; Crha I; Huser M; Weinberger V; Žáková J; Ješeta M; Lousová E; Filipinská E; Ventruba P Ceska Gynekol; 2017; 82(4):287-292. PubMed ID: 28925272 [TBL] [Abstract][Full Text] [Related]
11. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome. Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601 [TBL] [Abstract][Full Text] [Related]
12. Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report. Cai H; Shen H Braz J Med Biol Res; 2016; 49(6):e5227. PubMed ID: 27191608 [TBL] [Abstract][Full Text] [Related]
13. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489 [TBL] [Abstract][Full Text] [Related]
14. Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases. Saito S; Yamada M; Yano R; Takahashi K; Ebara A; Sakanaka H; Matsumoto M; Ishimaru T; Utsuno H; Matsuzawa Y; Ooka R; Fukuoka M; Akashi K; Kamijo S; Hamatani T; Tanaka M J Ovarian Res; 2023 Aug; 16(1):159. PubMed ID: 37563616 [TBL] [Abstract][Full Text] [Related]
15. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146 [TBL] [Abstract][Full Text] [Related]
16. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Domingo J; Guillén V; Ayllón Y; Martínez M; Muñoz E; Pellicer A; Garcia-Velasco JA Fertil Steril; 2012 Apr; 97(4):930-4. PubMed ID: 22283969 [TBL] [Abstract][Full Text] [Related]
17. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type. Lefebvre T; Mirallié S; Leperlier F; Reignier A; Barrière P; Fréour T Reprod Biomed Online; 2018 Aug; 37(2):201-207. PubMed ID: 29784618 [TBL] [Abstract][Full Text] [Related]
18. Luteal phase stimulation, the future of fertility preservation? Retrospective cohort study of luteal phase versus follicular phase stimulation. Jochum F; Sananès N; Teletin M; Lichtblau I; Rongières C; Pirrello O J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):91-94. PubMed ID: 30439518 [TBL] [Abstract][Full Text] [Related]
19. Random-start controlled ovarian hyperstimulation with letrozole for fertility preservation in cancer patients: case series and review of literature. Keskin U; Ercan CM; Yilmaz A; Babacan A; Korkmaz C; Duru NK; Ergun A J Pak Med Assoc; 2014 Jul; 64(7):830-2. PubMed ID: 25255597 [TBL] [Abstract][Full Text] [Related]
20. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]